A joint research team from The Hong Kong University of Science and Technology (HKUST), and the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) have demonstrated that ZCB11, a broadly neutralising antibody derived from a local mRNA-vaccinee against the spreading Omicron variants of SARS-CoV-2, displays potent antiviral activities against all variants of concern (VOCs), including the dominantly spreading Omicron BA.1, BA1.1 and BA.2. The research team members include (from left): Professor Dang Shangyu, Assistant Professor of Division of Life Science, HKUST and Professor Chen Zhiwei, Director of AIDS Institute of the University of Hong Kong and Professor of the Department of Microbiology, School of Clinical Medicine, HKUMed.
(From right) Carol CHAN, a final year HKUST student studying International Research Enrichment (Physics), Prof. Emily NASON, Director of Undergraduate Recruitment and Admissions at HKUST, and Ben CHAK, a year 2 HKUST computer science and engineering student
(From left) Carol CHAN, a final year HKUST student studying International Research Enrichment (Physics), Prof. Emily NASON, Director of Undergraduate Recruitment and Admissions at HKUST, and Ben CHAK, a year 2 HKUST computer science and engineering student
(From left) Carol CHAN, a final year HKUST student studying International Research Enrichment (Physics), Prof. Emily NASON, Director of Undergraduate Recruitment and Admissions at HKUST, and Ben CHAK, a year 2 HKUST computer science and engineering student
Prof. SHAO Minhua, Professor from HKUST’s Department of Chemical and Biological Engineering and the Director of HKUST Energy Institute, holds the prototype of the new hydrogen fuel cell.
